The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pazopanib in metastatic renal carcinoma (mRC): Experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice.
Angel Rodriguez Sanchez
Honoraria - GlaxoSmithKline
Rocio García Domínguez
Honoraria - GlaxoSmithKline
Guillermo De Velasco
Honoraria - GlaxoSmithKline
Alvaro Pinto
No relevant relationships to disclose
Javier Puente
Honoraria - GlaxoSmithKline
Gustavo Rubio
Honoraria - GlaxoSmithKline
Sergio Vazquez-Estevez
Honoraria - GlaxoSmithKline
Marta Juan
No relevant relationships to disclose
Manuel Constenla
Honoraria - GlaxoSmithKline
Marta Lopez Brea
Honoraria - GlaxoSmithKline
Maria Sereno
Honoraria - GlaxoSmithKline
Javier L. Puertas
Honoraria - GlaxoSmithKline
Maria Garrido
Honoraria - GlaxoSmithKline
David Marrupe
Honoraria - GlaxoSmithKline
Maria L Villalobos
Honoraria - GlaxoSmithKline
Blanca Cantos
Honoraria - GlaxoSmithKline
Teresa de Portugal
Honoraria - GlaxoSmithKline
Rocio Vilchez
No relevant relationships to disclose
Jose-Luis Gonzalez-Larriba
Honoraria - GlaxoSmithKline
Jose Angel Arranz Arija
Honoraria - GlaxoSmithKline